anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The present invention relates to biobased glyceryl heptanoate compositions, and preferably glyceryl monoheptanoate compositions, methods of manufacturing the same, as well as applications thereof including the use of the inventive compositions in formulations for cosmetics and other personal care applications. The biobased monoglyceryl monoester (MGME) compositions include a mixture including one or more compounds of Formula (I): R1, R2, and R3 are independently H or C(O)-C6 alkyl. The composition comprises greater than about 60 wt% and less than about 98 wt% glyceryl monoheptanoate. The carbon present in the one or more compounds of Formula (I) is biobased. The composition has an ET50 value of &gt;24 hr when tested as a 1% solution in water according to the EpiDerm Skin Irritation Test (OECD 439). The present invention also relates to microbiostatic concentrates (MBCs) including the disclosed composition.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a manufacturing method that can manufacture a soft capsule of a simple composition having an excellent mechanical strength, preservability, transparency and moldability without using raw materials regarded as an additive.  &lt;P&gt;SOLUTION: Modified starch is prepared by subjecting waxy corn starch to acid treatment or wet heat treatment in the presence of a salt. A capsule film solution is prepared by dissolving 100 pts.wt. of the modified starch and 20-28 pts.wt. of iota carrageenan in water under heating. A capsule film made from the capsule film solution is treated in a rotary-die molding apparatus to mold the soft capsule filled with contents.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
PURPOSE:To obtain the titled composition, by using a composition containing ethanol as an active ingredient and an extract of plants selected from Polygala senega L., Eugenia caryophyllata Thunb., Forsythia suspensa Vahl., etc., together, capable of moderating the irritation of the ethanol and sufficiently exhibiting antimicrobial effect and having excellent feeling of use. CONSTITUTION:A composition for the oral cavity obtained by blending a composition for the oral cavity containing ethanol in an amount of &gt;=5wt%, particularly 5-30wt% based on the total composition with one or two or more extracts of plants selected from Polygala senega L., Eugenia caryophyllata Thunb., Forsythia suspensa Vahl., Lonicera japonica, thunb., and Polygala tenuifolia Willd. The amount of the extracts of the plants blended with the composition is 0.0001-2%, particularly preferably 0.001-1% based on the total composition. As for the plants to be a raw material for the extracts, roots of the Polygala senega L. of the family Polygalaceae are effectively used particularly as the Polygala senega L. and flowered buds, barks, etc., of the Eugenia caryophyllata Thunb. of the family Myrtaceae are effectively used as the Eugenia caryophyllata Thunb. Fruits, pericarps, etc., of the genus Forsythia of the family Oleaceae are effectively used as the Forsythia suspensa Vahl., etc.
A novel TNF-preparation with high cytolytic activity is disclosed. The TNF preparation includes modified forms of tumor necrosis factor associated with the surface of liposomes of small diameter (between 0.02-0.05  mu m) known as SUV&#39;s. The tumor necrosis factor molecule is modified at up to 3 amino residues per trimer with nearly complete retention ( SIMILAR 80-95 %) of biological activity. The modified TNF amino residues are modified to include long chain fatty acids via TNF lysyl side chains and/or N-terminal amino groups. The disclosed modified TNF molecules provide a highly efficient method for preparing liposome-associated TNF complexes in either standard MLVs or SUVs having enhanced in vivo stability. The binding of said modified TNF molecules to the surface of small unilamellar vesicles is with up to 100 % efficiency. Pharmacologically acceptable preparations of modified TNF for the particular treatment of TNF-responsive tumors are also provided. Methods of preparing liposome associated-lipophilic TNF molecules are provided. The liposomes of the present invention are decribed as small unilamellar vesicles (SUV). The liposomes of the present invention feature particularly small diameters in the range of 0.02 - 0.05  mu m in diameter. Highly efficient methods of preparing stable, surface-associated protein liposome complexes having enhanced stability in vivo are also provided.
PURPOSE:To provide a fat transfusion liquid containing high-purity eicosapentaenoic acid triglyceride, exhibiting platelet coagulation inhibiting action at a low dose without causing supernutrition, hyperlipemia and hepatic function disorder and useful for the remedy and prevention of thrombotic diseases. CONSTITUTION:High-purity eicosapentaenoic acid triglyceride (abbreviated as EPA-TG) is dispersed together with an emulsifier and glycerol in distilled water and emulsified under pressure to obtain a fat transfusion liquid. The high-purity EPA-TG can be produced by reacting preferably &gt;=90% EPA with glycerol in the presence of a condensation agent. Significant lowering of platelet coagulation takes place with little increase in blood lipid level and GPT by the administration of the high-purity EPA-TG transfusion liquid twice at a rate of 30ml/dose. The transfusion can be advantageously used as a medicinal drug. Fish oil containing EPA used as a raw material can be effectively utilized.
An electronic intraocular device is implantable into the capsular bag of a wearer&#39;s eye. In some cases, the intraocular device may include a femtoprojector. The femtoprojector projects images onto the wearer&#39;s retina when the electronic intraocular device is implanted in the wearer&#39;s eye. Different haptic designs may be used to keep the femtoprojector in position. In some embodiments, an imager is contained in a contact lens worn by the wearer. Images captured by the contact lens imager may be relayed to the intraocular femtoprojector. In some cases, the intraocular device may include an electronic capsular tension ring with a femtoimager. The femtoimager may capture images of the wearer&#39;s retina, for example for purposes of monitoring eye health.
The present invention provides methods for direct killing of cancer cells using anti-alpha5beta1 antibodies. Generally, the method comprises contacting a cancer cell that expresses alpha5beta1 on its surface with an anti-alpha5beta1 antibody, and thereby inducing the death of the cancer cell. The methods of the invention may be employed at an early stage of cancer development in a patient to prevent tumor establishment. In addition, the methods may be used to treat previously formed tumors especially in cancer that have not proven susceptible to anti-angiogenesis therapy. The methods may be employed as a combination therapy of anti-alpha5beta1 antibodies together with cancer chemotherapeutic agents or other molecular-based cancer therapeutic agents. ® KIPO &amp; WIPO 2007
FIELD: medicine, pharmaceutics. SUBSTANCE: innovation deals with pharmaceutical preparations of ibandronate or its physiologically acceptable salts for oral usage. It represents a medicinal product to treat hypercalcemia, osteoporosis, tumor osteolysis, Paget&#39;s disease. Said product is represented by film-covered ibandronate tablets being nonresistant to gastric juice which release, at least, 30% dosage of active substance at contact with aqueous medium at pH ranged 1-7.4 for 2 h. Said medicinal product enables to decrease side effects, to prevent esophagitis, in particular. EFFECT: higher efficiency. 8 cl
1277239 1- Phenyl - cycloalkane - 1 - carboxylic acids;. TAKEDA YAKUHIN KOGYO KK 4 July 1969 [4 July 1968 13 July 1969 18 Jan 1969] 33732/69 Heading C2C Novel 1 - phenyl - cycloalkane - 1 - carboxylic acids of the general formula wherein X is a hydrogen or halogen atom, R is a C 3-6  alkyl or cycloalkyl group and n is an integer of from 2 to 5, and pharmaceutically acceptable salts or derivatives thereof derived by conversion of the carboxylic group, i.e. acid amides and esters and hydroxamic acids, are prepared (a) by reaction of a phenyl-acetonitrile of the. general formulawith an alkylene halide of the general; formula X&lt;SP&gt;1&lt;/SP&gt;(CH 2 ) n X&lt;SP&gt;1&lt;/SP&gt;, wherein X&lt;SP&gt;1&lt;/SP&gt; is a halogen atom, followed optionally by halogenation and/or hydrolysis. of the resulting 1-phenyl-cycloalkane-1-nitrile of the general formula (b)- byhalogenation of a phenyl&#39;-acetonitrile of the second general. formula above and reaction of the resulting-phenyl-acetonitrile of the.general formula wherein X&lt;SP&gt;11&lt;/SP&gt; is a halogen atom, with an alkylene halide of the third general formula above, followed optionally by hydrolysis of the resulting 1-phenyl-cycloalkane-1-nitrile of the general formula and (c) when n is 2 ,by reaction of diazomethane with, an α-phenyl-acrylic acid of the general formula. or a pharmaceutically acceptable salt or deriva; tive thereof derived by conversion of the carboxylic group and denitrification of the resultting 3 - phenyl - 1 - pyrazoline - 3 - carboxylic acid of the general formula or pharmaceutically acceptable salt or derivative thereof derived by conversion of the carboxylic group, followed optionally by conversion of a resulting 1-phenyl-cycloalkane-1,-carboxylic acid of the first general formula above to a pharmaceutically acceptable salt or derivative thereof derived by conversion of the carboxylic group (other than a nitrile in the case of (a) and (b) above), or by conversion of a resulting pharmaceutically acceptable salt or derivative of a 1-phenyl-cycloalkane- 1 -carboxylic acid of the first general, formula above derived by conversion of the carboxylic group to the free acid. Pharmaceutical compositions having antiinflammatory activity comprise, as active ingredient, a 1-phenylcycloalkane-carboxylic acid of the first general formula above or a pharmaceutically acceptable salt or derivative thereof derived by conversion of the carboxylic group, in admixture with a pharmaceutically acceptable carrier or adjuvant, and may be administered orally or by way of injection.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new hematopoietic cell growth stimulator useful for therapy or the like of thrombopenia and having thrombopoietin-like bioactivity.  &lt;P&gt;SOLUTION: The peptide includes the amino acid sequence: Ile-Glu-Gly-Pro-Thr-Leu-Arg-Gln-Trp-Leu-Ala-Ala-Arg-Ala-Cys (sequence number 1). The hematopoietic cell growth stimulator contains the peptide. Preferably, the hematopoietic cell growth stimulator contains a metal and the peptide bonded to the metallic particles. The medicine contains them. The hematopoietic cell growth stimulator is safe without side effect, and includes hematopoietic cell growth-stimulating activity comparative with thrombopoietin.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
ABSTRACT         This specification discloses oral or edible compositions and their manufacture.  It includes foods and pharmaceutical preparations containing sugar and very little water.  In particular it discloses hygienic agents for tooth and mouth care.  It is known that in the oral cavity foodstuffs, beverages and medicaments with a high sugar content lead, in the presence of micro-organisms, to the formation of so-called &#34;plaques&#34; and acid decomposition products which severely attach tooth enamel.  This effect is known by the name caries.  Caries is understood to be an initial attack on the surface of teeth which are then progressively destroyed by cavities being formed therein.  Thus the specification discloses an edible or oral composition which composition contains sugar and very little water and having a content of the enzymes lactate dehydrogenase and saccharose - inverting enzyme which limits promotion of tooth decay.  It appears that by adding lactate dehydrogenase in combination with a sucrose-inverting enzyme, an inhibition system is incorporated into foodstuffs and con-fectionery of low water content or containing no water, and when these products are eaten, this system counteracts the harmful effect, in the presence of cariogenic bacteria, of the products formed by the decomposition of sugars, and converts the food-stuffs, in particular confectionery, and the pharmaceutical preparations into non-cariogenic or anticariogenic foodstuffs and pharmaceutical preparations which are not harmful to teeth.          This preferably comprises foodstuffs with a residual moisture content of 0.1 to 2%.  It includes foodstuffs which contain a proportion of naturally occurring sugars, such as sucrose, glucose, fructose and the like, as well as sugar alcohols, as - a -sugar substitutes.  Foodstuffs containing sucrose are particularly preferred.  If appropriate, foodstuffs or con-fectionery or pharmaceutical preparations which contain no customary sugars can be used.  These can be materials which are sweetened on the basis of sugar substitutes, for example saccharin, cyclamate, protein sweeteners extracted from tropical plants, xylitol and the like.  The sugar containing foodstuff is intended in particular to comprise confectionery, such as bakery products, sweets, chewing gum, etc.     - b -
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a natural cosmetic improving the bleaching effect of a naturally derived cosmetic along with yielding the effect of preventing or ameliorating rough skin.  &lt;P&gt;SOLUTION: The natural cosmetic is obtained by the following procedure: The whole grass of the leaves, stems and roots of Houttuynia cordata is finely chopped and washed with water and then soaked in 70 mL of rice Shochu(Japanese white distilled liquor) 20% in alcohol concentration at room temperature in a dark place for one month. The solids are then filtered off to obtain an alcohol extract liquid of Houttuynia cordata. Whereas, 100 g of dried white mulberry root bark is soaked in 400 mL of an aqueous alcohol solution that is prepared from 300 mL of anhydrous ethanol and 100 mL of purified water, left at rest at room temperature in a dark place for one week. The solids are then filtered off to obtain an alcohol extract liquid of white mulberry root bark. The objective cosmetic, a bleaching skin lotion, is obtained by adding 1.4 mL of the alcohol extract liquid of white mulberry root bark to 100 mL of the alcohol extract liquid of Houttuynia cordata. This skin lotion has bleaching effect about 1.5-2 times that of Houttuynia cordata and white mulberry root bark each, having the effects of preventing and ameliorating rough skin as well.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a hepatic disease-preventing and treating agent which can suitably be used for preventing and treating at least one hepatic disease selected from acute and chronic viral hepatitis, acute and chronic drug hepatitis and fulminant hepatitis, and to provide a hepatic disease-preventing and treating food or drink containing the hepatic disease-preventing and treating agent.  &lt;P&gt;SOLUTION: The hepatic disease-preventing and treating agent is characterized by containing a bisabolane type sesquiterpene compound. The bisabolane type sesquiterpene compound is preferably originated from a plant of the genus Curcuma, the family Zingiberaceae. The bisabolane type sesquiterpene compound is preferably at least one compound selected from ar-turmerone, α-turmerone, β-turmerone and their mixtures. The hepatic disease-preventing and treating food or drink is characterized by containing the bisabolane type sesquiterpene compound.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide fermented milk having new function of relation with I-type allergy clarified on scientific grounds, and to provide fermented milk production spawn to be used for producing the fermented milk.  &lt;P&gt;SOLUTION: The fermented milk contains the fungus body or fungus body component of a plurality kinds of lactic acid bacteria composed of Lactobacillus casei, Lactobacillus plantarum, Lactococcus lactis subsp. lactis, and Lactococcus lactis subsp. cremoris. It is possible to induce interferon-gamma expression and adjust Th1/Th2 balance to Th1 domination by daily eating the fermented milk. As a result of this, generation of IgE is inhibited to inhibit appearance of I type allergy. The fermented milk production spawn to be used for producing the fermented milk contains the lactic acid bacteria.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
An electronic record system and method to operate a state licensed facility. The records system of the present invention meets the daily needs of the administrator and staff caring for the resident in a residential care setting. Services provided by staff include activities of daily living and medication administration for residents. As staff document a care note the records system transfers this data to a central timeline for that resident. This timeline shows a user all medications given as well as ADL&#39;s, IADL&#39;s and care notes. The present invention will streamline all required documents for the Facility, Staff and Resident. This invention digitalizes the process of operating a State licensed Residential Care Facility for the Elderly (RCFE) and Adult Residential Facility (ARF). This invention helps the facility owner maintain compliance allowing more efficiently in are for the residents. This invention and method allow for Regulatory and licensing agency to access and verify document compliance for each facility. This method and process allows for facility owners and operators to access required documents in the event originals are missing or damaged during disaster or for immediate need to review.
The present invention concerns the use of isolated secreted vesicles produced by enriched renal cell populations for providing a regenerative effected to a kidney.  Specifically, the vesicles may comprise exosomes that comprise a microRNA, and the microRNA rnay inhibit signaling of one or more of Plasminogen Activation Inhibitor-1, Transforming Growth Factor Beta or Nuclear Factor Kappa Beta.  The regenerative effect may be a reduction in renal fibrosis or inflammation.  Provided herein are also methods of assessing whether a kidney disease patient is responsive to treatment with a therapeutic comprising a population of renal cells enriched for tubular cells. The methods include a step of detecting the amount of a marker associated with vesicles in a test urine sample of a patient treated with the therapeutic relative to the amount of the marker associated with the vesicles in a control urine sample. In the method, a higher or lower amount of the marker associated with the vesicles in the control sample compared to the test sample is an indication of thc patient&#39;s responsiveness to the therapeutic.
Squamous cell carcinomas of the head and neck region (HNSCC) form a group of metastasizing tumours with a high mortality rate in humans and animals. Since it has been discovered that the biomolecule ozone inhibits the growth of various carcinoma cells in vitro, we have used the highly aggressive and lethal VX2 carcinoma of the New Zealand rabbit as HNSCC tumour model in order to test whether ozone has antitumour effects in vivo. Therapeutic insufflation of a medical ozone/oxygen (O3/O2) gas mixture into the peritoneum (O3/O2 pneumoperitoneum) at an advanced stage of a neoplastic disease led to a survival rate of 7/14 rabbits. Six of the seven surviving rabbits showed a complete tumour regression and the absence of local or remote pulmonary metastases. Insufflation of pure oxygen (O2) led to a survival rate of 3/13 animals, which was associated with complete tumour remission in two of the three surviving animals. Of the fourteen sham-treated animals, only one developed spontaneous tumour remission and survived. No side effects or changes in standard blood parameters were observed after repeated intraperitoneal insufflations with O3/O2 or O2 gas. Animals with O3/O2-induced tumour regression developed tolerance to reimplantation of the VX2 tumour. It was possible to reverse this by immunosuppression with a combination of dexamethasone and cyclosporin A, suggesting that the O3/O2-mediated activation of the body&#39;s immune surveillance has an antitumor effect. Although the exact mechanisms of action are still unclear, the available data indicates that O3/O2 pneumoperitoneum is a promising new strategy in tumour therapy.
PURPOSE:To improve the stability of a plasminogen activator in the treatment such as the storage, separation, purification, freeze-drying, etc., and to keep its activity, by adding albumin to a novel plasminogen activator collected from the tissue culture liquid of the cell originated from the normal human tissue. CONSTITUTION:A cell capable of producing plasminogen activator, preferably the cell of lung, kidney and sheath of human fetus, is cultured in various culture liquids, and a novel plasminogen activator is separated from the resultant tissue culture liquid. The plasminogen activator has the following characteristics: molecular weight, 63,000+ or -10,000; isoelectric point, 7.0-8.5; having affinity with fibrin and concanavalin A; optimum pH, 7-9.5; inert to the anti-urokinase specific antibody; etc. The activator can be stabilized by the addition of albumin. The amount of the albumin is selected to give the activator-containing solution having an albumin content of &gt;=1mg, preferably &gt;=5mg per 1ml of the solution. The thrombolytic activity of the activator is 30 times stronger than that of urokinase.
Novel substituted xanthines having general formula &lt;FORM:1079267/C2/1&gt; &lt;FORM:1079267/C2/2&gt; wherein A is an alkylene group having 3-6 carbon atoms, and B is an alkylene group having 2-5 carbon atoms, A and B may be unbranched or may contain an alkyl substituent, having 1-4 carbon atoms, on the carbon atom adjacent to the carbonyl group, and the keto group is at a distance of 2-5 carbon atoms from the xanthine nucleus, prepared by:-  (a)  Reaction of theophylline or theobromine, at elevated temperature and in alkaline media, with an a ,b -unsaturated methyl ketone, which may be substituted by an alkyl group of 1-4 carbon atoms, at the b position.  (b)  Reaction of a b -dialkylaminoethyl methyl ketone, the alkyl groups of which have 1 or 2 carbon atoms, with theobromine in an aqueous organic solution.  (c)  Reaction of an (o -1) oxyhalide of formula CH3-CO-A-Hal or CH3-CO-B-Hal, in which A and B are as defined above and Hal represents halogen, with an alkali-metal salt of theophyline or theobromine.  (d)  Reaction of an 1(o -haloalkyl)-3,7-di-methyl xanthine or 7-(o -haloalkyl)-1,3-dimethyl xanthine with an alkali metal salt of ethyl acetoacetate, and subjecting the reaction product to ketonic hydrolysis. 2,4-Dinitrophenyl hydrazones of the above xanthines are mentioned. 2-Methyl-3-carbethoxy-dihydropyrane is prepared by condensing a 1,3-dihalopropane with one mol of ethyl acetoacetate and either 2 mols of metallic sodium in absolute ethanol or at least 2 mols of anhydrous potassium carbonate in at least 90% ethanol. 1-Halohexanone-5 is prepared by refluxing 2-methyl-3-carbethoxy-dihydropyrane with at least two mols of hydrogen halide.ALSO:Pharmaceutical compositions having vasodilatory activity, and which may be administered orally or parenterally in the form of capsules, tablets, coated tablets, solutions or suspensions, contain a 1-[(w-1)-oxoalkyl]-3, 7-dimethyl xanthine or a 7-[(w-1)-oxoalkyl]-1,3-dimethylxanthine as the active ingredient in association with a pharmaceutical carrier.  The oxoalkyl dimethylxanthines [which are soluble in water to the extent of 4% or more], considerably improve the water solubility of other pharmaceutically active compounds which are sparingly soluble such as pentacrythritol tetranicotinate, rutine, reserpine, khelline, theobromine, glycerol trinicotinate, 5-phenyl-5-(3\sv -oxobutyl)-barbituric acid, 1-hexyl-3,7-dimethylxanthine ergotamine tartrate, o-phenylacetyl-N-acetyl corynanthine, caffeine, yohimbine, theophylline or an acid addition salt thereof.